Bay News 9Priority Health: RA treatmentBay News 9Abatacept is available as both an infusion and a self-injection, as noted above. Infliximab is given during a two-hour procedure every two to eight weeks. Rituximab is given over several hours. You may r…
Clinical Oncology NewsFludarabine Plus Rituximab Assessed in Relapsed/Refractory HCLClinical Oncology NewsA team of researchers from Vancouver, British Columbia, has found that treatment with combination therapy of fludarabine (Fludara, Genzyme; variou…
Plant-Made Pharmaceuticals And The Democratization Of Health CareSeeking AlphaThe Ibiolaunch has successfully expressed both humanized and chimeric monoclonal antibodies, Paviluzumab and Rituximab, respectfully. Astrazeneca (AZN), parent of MedImmune, …
OncLiveEmerging Markers Point to Future Strategies in CLL: An Interview With William …OncLivePlease discuss your research into fludarabine, cyclophosphamide, and rituximab (FCR)-based treatment for CLL. 1 Assume you have a patient who has developed a…
Gilead Sciences Management Discusses Q1 2012 Results – Earnings Call TranscriptSeeking AlphaAs a final R&D highlight, 3 Phase III studies will be initiated in patients with relapsed or refractory chronic lymphocytic leukemia, or CLL, which is 1101 …
The GuardianDrug company attacks Nice for rejecting new lupus treatmentThe GuardianThe standard treatment usually consists of non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and/or immunosuppressants such as rituximab in some cases. Ar…
Clinical Oncology NewsAdjuvant Radiation After R-CHOP-14 Increases Lymphoma SurvivalClinical Oncology NewsWhile the addition of rituximab had clearly contributed to increased response rates, event-free survival and OS in PMLBCL, the role of radiotherap…
Spectrum Pharmaceuticals Reports Record Revenues and Profits for First Quarter …MarketWatch (press release)Conduct the "ZAR" trial, a head-to-head study vs. rituximab maintenance in follicular non-hodgkin's lymphoma in North America Spe…
Patients Drop MS Drug, Face Relapse RiskMedPage TodayOf the nine patients who switched away from natalizumab, seven chose injectable drugs including interferon-beta products, glatiramer acetate (Copaxone), or rituximab (Rituxan). Two chose the oral dru…
Global framework for biosimilars "is now crucial"Pharma TimesGiven the upcoming patient expiries on a number of major biologic drugs, including Roche's Herceptin (trastuzumab) and Rituxan (rituximab), Sanofi's Lantus Insulin glargine)…